Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not. Objective: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA). Methods: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019. Results: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cy- closporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persis- tence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively. Conclusion: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.
Abstract
Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not. Objective: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA). Methods: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019. Results: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cy- closporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persis- tence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively. Conclusion: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.
참고문헌 (24)
- Menter A, "Drug survival of biologic therapy in a large, diseasebased registry of patients with psoriasis : results from the Psoriasis Longitudinal Assessment and Registry(PSOLAR)", J Eur Acad Dermatol Venereol, 30, pp.1148~1158 (2016)
- Cheng J, "The cost of biologics for psoriasis is increasing", Drugs Context, 3, pp.212266~ (2014)
- Costanzo A, "Effectiveness end points in real-world studies on biological therapies in psoriasis : systematic review with focus on drug survival", Dermatology, 234, pp.1~12 (2018)
- van den Reek JMPA, "Drug survival studies in dermatology : principles, purposes, and pitfalls", J Invest Dermatol, 135, pp.1~5 (2015)
- Gniadecki R, "Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris", Br J Dermatol, 172, pp.244~252 (2015)
- Langley RG, "Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis : results from the PHOENIX 2 study through 5 years of follow-up", Br J Dermatol, 172, pp.1371~1383 (2015)
- Bissonnette R, "Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment(SCULPTURE Extension Study)", J Eur Acad Dermatol Venereol, 32, pp.1507~1514 (2018)
- Yiu ZZN, "Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis : a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register(BADBIR)", Br J Dermatol, 183, pp.294~302 (2020)
- Warren RB, "Differential drug survival of biologic therapies for the treatment of psoriasis : a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register(BADBIR)", J Invest Dermatol, 135, pp.2632~2640 (2015)
- Mourad A, "Factors predicting persistence of biologic drugs in psoriasis : a systematic review and meta-analysis", Br J Dermatol, 181, pp.450~458 (2019)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Kim L, "A guide for the utilization of health insurance review and assessment service national patient samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- Kishimoto M, "Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan", J Dermatol, 47, pp.33~40 (2020)
- Blauvelt A, "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year : results from the CLEAR study", J Am Acad Dermatol, 76, pp.60~69 (2017)
- Mourad AI, "Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis", Front Med (Lausanne), 7, pp.625755~ (2021)
- Ghoreschi K, "Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis", Lancet, 397, pp.754~766 (2021)
- Mahil SK, "Comparing the efficacy and tolerability of biologic therapies in psoriasis : an updated network meta-analysis", Br J Dermatol, 183, pp.638~649 (2020)
- Farhangian ME, "Immunogenicity of biologic treatments for psoriasis : therapeutic consequences and the potential value of concomitant methotrexate", Am J Clin Dermatol, 16, pp.285~294 (2015)
- Xu Z, "Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy and safety", J Clin Pharmacol, 55(3), pp.60~74 (2015)
- Shalom G, "Biologic drug survival in Israeli psoriasis patients", J Am Acad Dermatol, 76, pp.662~669 (2017)
- Ruyssen-Witrand A, "Efficacy and safety of biologics in psoriatic arthritis : a systematic literature review and network meta-analysis", RMD Open, 6, pp.e001117~ (2020)
- Lin PT, "Drug survival of biologics in treating psoriasis : a meta-analysis of real-world evidence", Sci Rep, 8, pp.16068~ (2018)
- Menter A, "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies", J Am Acad Dermatol, 82, pp.1445~1486 (2020)
- Kamata M, "Safety of biologics in psoriasis", J Dermatol, 45, pp.279~286 (2018)